Skip to main content

Advertisement

Table 2 Association between pathological findings and molecular profile

From: Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma

No. Sex Diagnostic procedure Smoking index EGFR mutation KRAS mutation ALK IHC Pathological features
Epithelial component Sarcomatoid component
1 M Surgery 2100 Wild Mutated Negative Adeno Giant cell > Spindle cell
2 F Surgery 0 Exon 19 del Wild Negative Adenosquamous Spindle cell > Giant cell
3 M Surgery 1200 Wild Wild Negative Adeno Spindle cell > Giant cell
4 F Surgery 0 Wild Wild Negative Adeno Spindle cell > Giant cell
5 M Surgery 400 Wild Wild Negative Adeno Spindle cell > Giant cell
6 M Surgery 1800 Wild Wild Negative Squamous Spindle cell > Giant cell
7 F Surgery 600 Wild Wild Negative Adeno Spindle cell > Giant cell
8 F Surgery 345 Wild Mutated Negative Large Giant cell > Spindle cell
9 M Autopsy 495 NA NA NA NOS Giant cell > Spindle cell
10 M Biopsy 2480 Wild Wild Negative NOS Giant cell
11 M Autopsy 480 Wild Wild Negative Adeno Giant cell
12 M Biopsy 1600 Wild Mutated Negative Squamous Spindle cell > Giant cell
13 M Surgery 660 Wild Wild Negative Large Giant cell > Spindle cell
14 M Autopsy 1160 Wild Wild Negative Adeno Giant cell > Spindle cell
15 F Surgery 0 Exon 21 L858R Wild Negative Large Spindle cell > Giant cell
16 F Biopsy 0 NA NA NA Large Spindle cell > Giant cell
  1. IHC immunohistochemistry, NOS not otherwise specified, Adeno adenocarcinoma, Squamous squamous cell carcinoma, Large large cell carcinoma, Adenosquamous adenosquamous carcinoma